These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35280654)

  • 1. ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD
    Malek R; Wu ST; Serrano D; Tho T; Umbas R; Teoh J; Lojanapiwat B; Ong TA; On WK; Thai SM; Kim J; Pophale R; Chiong E
    Transl Androl Urol; 2022 Feb; 11(2):179-189. PubMed ID: 35280654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study.
    Braeckman J; Michielsen D
    Arch Med Sci; 2014 Jun; 10(3):477-83. PubMed ID: 25097577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
    Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
    Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients.
    Tunn UW
    BMC Urol; 2011 Jul; 11():15. PubMed ID: 21801354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer.
    Ohlmann CH; Gross-Langenhoff M
    Urol Int; 2018; 100(1):66-71. PubMed ID: 29197875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
    J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.
    Shore N; Mincik I; DeGuenther M; Student V; Jievaltas M; Patockova J; Simpson K; Hu CH; Huang ST; Li Y; Lee Y; Chien B; Mao J
    World J Urol; 2020 Jan; 38(1):111-119. PubMed ID: 30941562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer.
    de Freitas CSM; Soares AN
    Int Braz J Urol; 2020; 46(3):383-389. PubMed ID: 32167701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.
    Wex J; Sidhu M; Odeyemi I; Abou-Setta AM; Retsa P; Tombal B
    Clinicoecon Outcomes Res; 2013; 5():257-69. PubMed ID: 23836996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety profiles of generic and branded leuprorelin acetate microspheres in patients with prostate cancer.
    Zhou Z; Zhou Y; Yan W; Feng T; Liang Z
    Oncol Lett; 2024 Jul; 28(1):319. PubMed ID: 38807677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligard: leuprolide acetate in a novel sustained-release delivery system.
    Sartor O
    Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
    Khan MS; O'Brien A
    Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.
    Solarić M; Bjartell A; Thyroff-Friesinger U; Meani D
    Ther Adv Urol; 2017 Dec; 9(6):127-136. PubMed ID: 28588651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
    Sharifi R; Knoll LD; Smith J; Kramolowsky E
    Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.